Literature DB >> 22759556

Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Dror Marchaim1, Bharath Sunkara, Paul R Lephart, Uma Mahesh Gudur, Ashish Bhargava, Ryan P Mynatt, Jing J Zhao, Suchitha Bheemreddy, Kayoko Hayakawa, Teena Chopra, Sorabh Dhar, Keith S Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22759556     DOI： 10.1086/666632

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


× No keyword cloud information.
  7 in total

1.  Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.

Authors:  Emily L Heil; J Kristie Johnson
Journal:  J Clin Microbiol       Date:  2016-01-20       Impact factor: 5.948

2.  Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.

Authors:  Yanjie Huang; Karen C Carroll; Sara E Cosgrove; Pranita D Tamma
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

3.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

Review 4.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

Review 5.  Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases.

Authors:  Jennifer Curello; Conan MacDougall
Journal:  J Pediatr Pharmacol Ther       Date:  2014-07

6.  Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption.

Authors:  Sofia Stokkou; Ina Tammer; Stefanie Zibolka; Christina Grabau; Gernot Geginat
Journal:  BMC Res Notes       Date:  2014-09-03

7.  Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia.

Authors:  Ruibin Wang; Sara E Cosgrove; Sarah Tschudin-Sutter; Jennifer H Han; Alison E Turnbull; Alice J Hsu; Edina Avdic; Karen C Carroll; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2016-06-20       Impact factor: 3.835
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.